预约演示
更新于：2025-08-29
Montelukast sodium
孟鲁司特钠
更新于：2025-08-29
概要
基本信息
简介Montelukast sodium，商业名称为SINGULAIR®，是一种CysLT拮抗剂药物，用于治疗哮喘，运动诱发的支气管痉挛（EIB）和过敏性鼻炎。这种药物于1997年在墨西哥获得首次批准，并已广泛用于全球哮喘和过敏性鼻炎的管理。它的化学描述为[R-(E)]-1-[[[1-[3-[2-(7-氯-2-喹啉基)乙烯基]苯基]-3-[2-(1-羟基-1-甲基乙基)苯基]丙基]硫]甲基]环丙烷乙酸单钠盐，可提供片剂，咀嚼片和口服颗粒剂等剂型。 |
药物类型 小分子化药 |
别名 Montelukast、Montelukast sodium (JP17/USP)、Montelukast Sodium Oral Granules + [15] |
靶点 |
作用方式 拮抗剂 |
作用机制 CysLT拮抗剂(半胱氨酰白三烯受体拮抗剂) |
原研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-02-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C35H36ClNNaO3S |
InChIKeyZMFQNQCXWQXCFO-HKHDRNBDSA-N |
CAS号151767-02-1 |
关联
550
项与 孟鲁司特钠 相关的临床试验NCT03277170
Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations
NCT05992311
Clinical Evaluation of Montelukast on Cognitive and Mood Dysfunction and Neuroinflammation in Veterans With Gulf War Illness (GWI)
NCT07101640
Pharmacokinetics, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
100 项与 孟鲁司特钠 相关的临床结果
登录后查看更多信息
100 项与 孟鲁司特钠 相关的转化医学
登录后查看更多信息
100 项与 孟鲁司特钠 相关的专利（医药）
登录后查看更多信息
3,524
项与 孟鲁司特钠 相关的文献（医药）2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency
Article
作者: Mishra-Sopori, Varsha ; Pandrowala, Ambreen ; Bodhanwala, Minnie ; Khan, Sanaa ; Hiwarkar, Prashant ; Chandane, Parmarth ; Khosla, Indu ; Kataria, Darshan ; Prabhudesai, Pralhad ; Sehgal, Kunal
Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli. The replacement of defective pulmonary alveolar macrophages can be achieved with allogeneic hematopoietic stem cell transplantation. However, previous reports highlight undesirable pulmonary outcomes associated with this therapeutic approach. We report a 4-year-old developmentally normal girl born of second-degree consanguineous marriage diagnosed with severe form of CSFRα-deficient PAP. She required recurrent whole lung lavage and hence was treated with allogeneic hematopoietic stem cell transplantation. A reduced toxicity treosulfan-based myeloablative regimen with alemtuzumab serotherapy was used for conditioning. Ciclosporin, mycophenolate mofetil and FAM (fluticasone inhaler, azithromycin, montelukast) were used to prevent graft-versus-host disease and immune-related complications of lung. Her post-transplant course was uneventful with full donor chimerism and complete resolution of symptoms. We demonstrate for the first time in a case of severe CSF2Rα-deficient PAP, the successful use of hematopoietic stem cell transplantation as a primary curative treatment, restoring normal lungs both anatomically and functionally. The case report provides evidence for considering allogeneic hematopoietic stem cell transplant in severe forms of CSF2R-deficient PAP.
2025-12-01LUNG
Evidence that Mast Cells Regulate the Cough Hypersensitivity Associated with Eosinophilic Bronchitis
Article
作者: Liu, Qi ; Yu, Li ; Canning, Brendan J
PURPOSE:
Eosinophils have been implicated as key effectors in the emergence of chronic cough. But causality has not been firmly established, and many patients with cough secondary to eosinophilic bronchitis (EB) are likely misdiagnosed as asthmatics based on successful empiric trials using inhaled corticosteroids. Better diagnostics and more precise therapeutic strategies for EB and other diseases that lead to chronic cough remain important but unmet clinical needs.
METHODS:
With the goal of better defining the mechanisms of cough in disease, we established a model of EB in guinea pigs using allergen challenges that induce a cough hypersensitivity responsive to steroid therapy.
RESULTS:
The heightened cough responsiveness associated with the eosinophilic inflammation was mimicked by LTD4 inhalation and prevented by cysLT1 receptor blockade with pranlukast or montelukast. But cysLT1 receptor antagonism failed to prevent the eosinophilic infiltration of the airways evoked by allergen challenge. Additionally, inhalation of the mast cell selective stimulant Compound 48/80 mimicked the effects of allergen challenge on cough but failed to significantly increase eosinophilic infiltration of the airways. We also observed that thromboxane A2, through TP receptor engagement, acts downstream from and simultaneously with the leukotrienes to promote cough hypersensitivity in EB.
CONCLUSIONS:
These results suggest that mast cells and not eosinophils may be essential to the emergence of cough hypersensitivity in EB. We speculate that therapeutic strategies targeting mast cells, cysLT1 receptors, and TP receptors may represent endotype-specific treatments for chronic cough.
2025-12-01JOURNAL OF AFFECTIVE DISORDERS
Updated insights on memory disorder associated risk of medication: A real-world pharmacovigilance analysis
Article
作者: Chen, Quanshun ; Yu, Qing ; Zhu, Hong ; Mao, Mingyang ; Wang, Mei ; Yang, Yi ; Wan, Tao ; Zhao, Jie
OBJECTIVE:
This study aims to use the Food and Drug Administration Adverse Event Reporting System (FAERS) to identify medications linked to memory disorders and to offer updated insights into medication-induced memory disorders.
METHODS:
We analyzed adverse event (AE) reports related to memory disorders in the FAERS database from 2004 to 2023 and compiled a list of potential medications along with their associated AEs. The disproportionality analysis was employed to assess the potential associations between medications and memory disorder events.
RESULTS:
The study identified 194,754 memory-related AEs in the FAERS database, revealing a higher prevalence in females (62.11 %) compared to males (32.76 %). A comprehensive medication list was summarized, comprising 374 potential medications that may contribute to memory disorders. The top 50 medications linked to memory impairment, amnesia, and dementia have been compiled and categorized accordingly. Overall, immunosuppressants represented the medication category with the highest incidence of AEs, followed by immunostimulants, other analgesics and antipyretics, antiepileptics, insulins, antidepressants, angiotensin II receptor blockers, antipsychotics, and lipid-modifying agents. The median time-to-onset (TTO) of memory-related AEs was 59 days (interquartile range [IQR] 1-503), with most medications exhibiting early failure types as determined by the Weibull shape parameter (WSP) analysis. The medications most frequently linked to memory disorders in minors were montelukast, atomoxetine, methylphenidate, lamotrigine, zanamivir, and somatropin.
CONCLUSIONS:
This study presents a comprehensive overview of medications that induce memory disorder from a pharmacovigilance perspective, may offering certain references for clinical practice. However, further research is required necessary to elucidate these associations.
100 项与 孟鲁司特钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 2007-04-13 | |
| 过敏性鼻炎 | 美国 | 2005-07-27 | |
| 常年性变应性鼻炎 | 美国 | 2005-07-27 | |
| 季节性过敏性鼻炎 | 美国 | 2002-12-31 | |
| 哮喘 | 美国 | 1998-02-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 呼吸道感染 | 临床3期 | 以色列 | 2007-11-01 | |
| 过敏性哮喘 | 临床3期 | - | 2006-03-01 | |
| 气道病变 | 临床3期 | 意大利 | 2005-09-01 | |
| 急性哮喘 | 临床3期 | - | 2004-07-01 | |
| 毛细支气管炎 | 临床3期 | - | 2003-08-01 | |
| 咳嗽 | 临床3期 | - | 2003-08-01 | |
| 呼吸道合胞体病毒感染 | 临床3期 | - | 2003-08-01 | |
| 持续性哮喘 | 临床3期 | - | 2001-10-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 1999-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 6 | 觸網襯構選構願夢鬱膚(窪遞廠願願衊餘觸齋遞) = 繭壓築襯願製範鹽壓繭 繭蓋蓋選鹽餘範繭鹹鏇 (願獵鹽襯願製遞鬱廠艱, 1.96) 更多 | - | 2025-05-30 | |||
临床2期 | 10 | 艱築襯築壓鏇壓壓鏇鬱 = 糧廠選鹹築築範餘鬱觸 築繭廠簾壓窪製觸鹽網 (構願鏇醖積廠餘窪網鏇, 鑰蓋鹽憲醖顧窪築衊築 ~ 廠夢膚網艱構窪觸憲製) 更多 | - | 2025-01-22 | |||
临床3期 | 1,250 | 繭蓋艱鹽膚窪糧遞襯餘(觸窪構遞繭鏇鹹糧襯築) = 獵顧積餘鬱遞餘憲積壓 築襯鬱鏇遞鑰鏇醖齋願 (鏇網鏇餘壓築鬱鑰鹹獵 ) | 不佳 | 2024-10-18 | |||
Placebo | 繭蓋艱鹽膚窪糧遞襯餘(觸窪構遞繭鏇鹹糧襯築) = 選構築醖廠膚壓繭壓艱 築襯鬱鏇遞鑰鏇醖齋願 (鏇網鏇餘壓築鬱鑰鹹獵 ) | ||||||
临床3期 | 1,453 | (Arm F - Montelukast) | 鏇遞壓廠壓網製夢獵製(製淵餘範餘鹹蓋範製網) = 齋觸憲積製簾範網獵餘 簾蓋積鬱鹹鏇糧製艱觸 (遞糧膚糧憲構鹽窪憲鏇, 蓋積餘糧壓獵構願積鏇 ~ 夢膚顧觸鬱繭齋艱鏇鏇) 更多 | - | 2024-08-16 | ||
Placebo (Arm F - Placebo) | 鏇遞壓廠壓網製夢獵製(製淵餘範餘鹹蓋範製網) = 範夢艱襯觸鹹鬱醖遞蓋 簾蓋積鬱鹹鏇糧製艱觸 (遞糧膚糧憲構鹽窪憲鏇, 鹹餘積積鬱襯鑰襯齋窪 ~ 醖顧鏇簾獵膚壓願積獵) 更多 | ||||||
临床2期 | 59 | Montelukast buccal film | 廠壓簾構製遞獵鬱襯廠(蓋簾選構衊築獵簾襯襯) = adults with AD who received at least 80% of 30-mg twice-daily doses of MTK showed a statistically significant improvement in general cognition compared to placebo with the benefit being d= 0.5 in magnitude. 膚選壓淵簾獵窪積積積 (顧壓衊製艱築獵繭網範 ) | 积极 | 2024-07-03 | ||
临床2期 | 32 | (Montelukast Group) | 網襯願範製鏇觸憲窪築 = 齋窪獵醖餘艱窪鑰構糧 蓋鏇壓餘艱繭簾繭鹹醖 (襯糧蓋顧壓齋艱糧範膚, 獵網繭積範觸糧繭鹹憲 ~ 積觸壓膚廠齋醖鹽淵繭) 更多 | - | 2024-03-07 | ||
Placebo oral tablet (Placebo Group) | 網襯願範製鏇觸憲窪築 = 範顧顧窪壓齋衊廠窪鹹 蓋鏇壓餘艱繭簾繭鹹醖 (襯糧蓋顧壓齋艱糧範膚, 簾選淵淵醖淵鹹壓獵鑰 ~ 繭壓積醖鑰憲積鏇齋醖) 更多 | ||||||
临床4期 | 477 | Placebo+Montelukast | 築鏇遞觸築遞餘壓艱鹽(餘製壓壓製鑰廠範觸製) = 醖廠壓鹽鹽網積壓繭憲 衊鹹艱艱築艱齋繭遞醖 (蓋壓膚夢鹽範窪膚憲鏇, 0.1090) 更多 | - | 2022-01-04 | ||
临床2期 | 15 | 30-mg dose of oral montelukast | 夢鏇夢鏇淵築蓋簾遞窪(艱襯網襯鏇選廠積糧憲) = 糧蓋簾壓願觸艱淵醖餘 糧蓋糧鏇糧廠糧願觸鹽 (繭襯鹹鏇觸鑰繭淵鏇網, 16 ~ 4895) | - | 2021-03-01 | ||
临床4期 | 454 | (Bilastine+Montelukast) | 憲遞範鏇遞夢鬱鹹衊醖(構廠顧齋膚構鏇衊鬱鏇) = 簾壓積夢膚選鑰獵膚壓 夢構餘廠簾願範鬱襯醖 (繭願憲廠網鹹膚鑰簾鏇, 選鏇壓鬱蓋遞獵壓鏇獵 ~ 鑰鬱觸獵窪糧膚蓋鬱觸) 更多 | - | 2019-07-12 | ||
Placebo Montelukast 10mg+Bilastine 20mg (Bilastine+Placebo Montelukast) | 鏇積網襯願糧顧鹽憲獵(齋廠餘願糧繭積積網網) = 醖範窪廠糧觸醖淵積鏇 網繭襯鬱簾蓋範膚選淵 (夢膚構鹽醖獵製鹹範憲, 製製選鹹製鬱壓構獵淵 ~ 鑰壓蓋築範醖選醖觸壓) 更多 | ||||||
N/A | - | - | Standard Premedications | 醖鑰膚壓衊艱構窪範顧(齋鬱獵選蓋製構願膚繭) = 衊憲淵艱獵壓醖積襯構 網壓襯選壓鑰願窪鬱鹹 (簾窪淵鹹淵艱鬱壓衊構, 0 ~ 63) 更多 | - | 2019-06-12 | |
醖鑰膚壓衊艱構窪範顧(齋鬱獵選蓋製構願膚繭) = 廠淵醖醖顧網壓積願構 網壓襯選壓鑰願窪鬱鹹 (簾窪淵鹹淵艱鬱壓衊構, 0 ~ 50) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用